Assembly Biosciences Inc (ASMB) Q1 2016 10-Q Quarterly Earnings

Short answer

Assembly Biosciences Inc (ASMB) filed its Q1 2016 10-Q quarterly report on May 10, 2016 for the quarter ended Mar 31, 2016.

AI summary of MD&A and risk factor updates

Quarterly revenue $0, unchanged YoY, with no approved products or product sales
Operating loss $11.0M, versus approximately $7.1M YoY
R&D expense $7.4M, up 166.3% from $2.8M, led by HBV-cure and microbiome programs
Operating cash used $9.2M, versus $3.7M YoY; no financing cash flow
Clinical trials expected in second half of 2016; cash, equivalents and securities sufficient for at least twelve months

No material changes identified from the most recent 10-K, with risks largely carried forward
Liquidity: resources expected to fund operations into fourth quarter 2017, but additional financing required thereafter
Regulatory: product candidates remain preclinical, requiring FDA approval before commercialization
Operational: reliance on third-party CROs and manufacturers could delay development or regulatory approval
Intellectual property: no issued patents currently cover product candidates, leaving competitive protection uncertain

Generated from the filing text; verify against the original. 10-K vs 10-Q vs 8-K

Compare quarters, check guidance or see what insiders and funds did around the report.